Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
IMRN - Immuron Limited
$6.87
-0.04(-0.58%)9:00:00 PM 1/15/2021
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.
Stock Chart

Summary:

  • A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics

Stock news

    01/11/2021IMRN
    Immuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference

    MELBOURNE, Australia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today is pleased to announce that Chief Executive Officer, Dr Jerry Kanellos, will participate in the H.C. Wainwright & Co. BioConnect 2021 Virtual Conference in January 2021 during J.P. Morgan week. Details of the events are as follows: * H.C...

    12/15/2020IMRN
    Immuron SARS-CoV-2 Research Agreement with Monash University

    Key Points * Immuron’s Hyper-immune Bovine Colostrum, used to manufacture Travelan® and Protectyn®, demonstrated antiviral activity against the SARS-CoV-2/COVID-19 virus in laboratory studies. * A New Research Services Agreement has been executed with Monash University to advance the SARS-CoV-2 findings and to further research and identify the inhibitory substance/s in Immuron’s marketed products (IMM-124E). MELBOURNE, Australia, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: I...

    11/24/2020IMRN
    Immuron Receives AUD $358,280 R&D Tax Concession Refund

    MELBOURNE, Australia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of AUD $358,280 for eligible research and development expenditure incurred during the ...

    11/11/2020IMRN
    US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine

    Key Points * NMRC demonstrated functional antibodies in new oral therapeutic targeting Campylobacter and ETEC * Immuron executes a Research Agreement with PCI Clinical Services to manufacture drug product * Two human phase II clinical trials to be conducted in 2021 by the US NMRC * One trial will focus ETEC infections * The second trial will focus on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobacteriosis MELBOURNE, Australia, Nov. 11, ...

    10/12/2020IMRN
    Immuron Travelers’ Diarrhea Market Update

    Key Points * Immuron’s IMM-124E IND Program recommences * Uniformed Services University to recommence planned Travelers’ Diarrhea clinical study * COVID-19 \- Consultancy Agreement with Infectious Disease Epidemiologist at Wayne State University MELBOURNE, Australia, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut medi...

    07/23/2020IMRN
    Immuron Limited Announces Closing of $20.0 Million Registered Direct Offering

    MELBOURNE, Australia, July 23, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), (the “Company”), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today announced the closing of its previously announced registered direct offering of 1,066,668 American Depositary Shares (“ADSs”), each representing forty (40) of the Company’s ordinary shares, at a purchase price of ...

    07/22/2020IMRN
    Introducing Immuron (ASX:IMC), The Stock That Soared 387% In The Last Year

    While stock picking isn't easy, for those willing to persist and learn, it is possible to buy shares in great...